Edition:
United States

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

17.82USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$17.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$24.50
52-wk Low
$16.11

Chart for

About

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally... (more)

Overall

Beta: --
Market Cap(Mil.): $580.78
Shares Outstanding(Mil.): 32.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-Deciphera Pharma reports data from ongoing phase 1 clinical study of DCC-2618 

* Deciphera Pharmaceuticals reports data from ongoing phase 1 clinical study of DCC-2618 at the 22nd annual scientific meeting and education day of the society for neuro-oncology Source text for Eikon: Further company coverage:

Nov 20 2017

BRIEF-Deciphera Pharmaceuticals Q3 loss $5.85 per share​

* Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights

Nov 14 2017

BRIEF-New Leaf Venture reports 12.9 pct stake in Deciphera Pharmaceuticals

* New Leaf Venture Management III LLC reports 12.9 percent stake in Deciphera Pharmaceuticals as of Oct 2 - SEC filing‍​ Source text:[http://bit.ly/2gwqdFF] Further company coverage:

Oct 11 2017

BRIEF-Viking Global Investors reports 8.1 pct passive stake in Deciphera Pharmaceuticals

* Viking Global Investors LP reports 8.1 percent passive stake in Deciphera Pharmaceuticals LLC ‍​as of Oct 2 - SEC filing‍​ Source : (http://bit.ly/2z0WbAm) Further company coverage:

Oct 11 2017

BRIEF-Deciphera Pharmaceuticals shares open 17.9 pct above IPO price in debut

* Deciphera Pharmaceuticals shares open at $20.05 in debut on NASDAQ vs IPO price of $17 per share Further company coverage:

Sep 28 2017

BRIEF-Deciphera Pharmaceuticals prices initial public offering of 7.5 mln shares at $17 per share

* Deciphera Pharmaceuticals announces pricing of initial public offering

Sep 27 2017

Earnings vs. Estimates